-

Iceland Insurance Industry Governance, Risk and Compliance (GRC) Analysis Report 2024 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Iceland Insurance Industry - Governance, Risk and Compliance" report has been added to ResearchAndMarkets.com's offering.

The report provides detailed analysis of the insurance regulations for life, property, motor, liability, personal accident and health, and marine, aviation and transit insurance. The report specifies various requirements for the establishment and operation of insurance and reinsurance companies and intermediaries.

The report brings together the analyst's research, modeling and analysis expertise, giving insurers access to information on prevailing insurance regulations, and recent and upcoming changes in the regulatory framework, taxation and legal system in the country. The report also includes the scope of non-admitted insurance in the country.

The report provides insights into the governance, risk, and compliance framework pertaining to the insurance industry in Iceland, including:

  • An overview of the insurance regulatory framework in Iceland.
  • The latest key changes, and changes expected in the country's insurance regulatory framework.
  • Key regulations and market practices related to different types of insurance product in the country.
  • Rules and regulations pertaining to key classes of compulsory insurance, and the scope of non-admitted insurance in the country.
  • Key parameters including licensing requirements permitted foreign direct investment, minimum capital requirements, solvency and reserve requirements, and investment regulations.
  • Details of the tax and legal systems in the country.

Key Highlights

  • The FME regulates and governs the Icelandic insurance industry.
  • Solvency II was incorporated into the Insurance Act on October 1, 2016 when the new Act No. 100/2016 on Insurance Activity came into effect.
  • FDI up to 100% is permitted in the Icelandic insurance industry.
  • Fire insurance for buildings, personal accident insurance for drivers of motor vehicles, motor third-party liability insurance, Iceland catastrophic insurance are the classes of compulsory insurance in Icelandic insurance industry.
  • Non-admitted insurance is not permitted in Iceland. However, EEA member state insurance companies are permitted to underwrite and sell non-admitted insurance contracts.

Scope

  • The report covers details of the insurance regulatory framework in Iceland.
  • The report contains details of the rules and regulations governing insurance products and insurance entities.
  • The report lists and analyzes key trends and developments pertaining to the country's insurance regulatory framework.
  • The report analyzes the rules and regulations pertaining to the establishment and operation of insurance businesses in the country.
  • The report provides details of taxation imposed on insurance products and insurance companies.

Reasons to Buy

  • Provides FAQ-style analytical insights comprising 129 knowledge elements on insurance compliance applicable to the country.
  • Gain insights into the insurance regulatory framework in Iceland.
  • Track the latest regulatory changes, and expected changes impacting the Icelandic insurance industry.
  • Gain detailed information about the key regulations governing the establishment and operation of insurance entities in the country.
  • Understand key regulations and market practices pertaining to various types of insurance product.

For more information about this report visit https://www.researchandmarkets.com/r/7lzw78

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

The Role of the Person Responsible for Regulatory Compliance (PRRC) Under the MDR (Medical Device Regulation) and IVDR (In-Vitro Diagnostic Regulation) Training Course (ONLINE EVENT: May 22, 2025) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "The Role of the Person Responsible for Regulatory Compliance (PRRC) Under the MDR (Medical Device Regulation) and IVDR (In-Vitro Diagnostic Regulation) Training Course" training has been added to ResearchAndMarkets.com's offering. Attend this one-day course to gain a comprehensive understanding of the critical role of the Person Responsible for Regulatory Compliance (PRRC) introduced by the Medical Device Regulation 2017/745 and the In-Vitro Diagnostic Device Regul...

Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course: Navigate CIS Pharmaceutical Markets with Expert Guidance on Evolving Regulations (ONLINE EVENT: June 19-20, 2025) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" training has been added to ResearchAndMarkets.com's offering. This interactive course will guide you through national procedures as well as explore the implications of and updates on the Eurasian Union regulation. The focus of the programme is to offer practical advice in developing your regulatory strategy for product approval in these countries and you will get the full benefit of...

U.S. Orphan Designated Drugs Market Research Report 2025: $190 Billion Opportunities, Drugs Sales, Price, Dosage & Clinical Trials Insights to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "U.S. Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Report Offering & Highlights: U.S. Orphan Designated Drugs Market Opportunity: > U.S.$ 190 Billion by 2030 Insight on FDA Designated Orphan Drugs in Clinical Trials: > 850 Orphan Drugs Clinical Trials Insight by Company, Indication, Phase & Priority Status Insight on FDA Designated...
Back to Newsroom